139 related articles for article (PubMed ID: 7613632)
1. Complex deficits on reaction time performance following bilateral intrastriatal 6-OHDA infusion in the rat.
Amalric M; Moukhles H; Nieoullon A; Daszuta A
Eur J Neurosci; 1995 May; 7(5):972-80. PubMed ID: 7613632
[TBL] [Abstract][Full Text] [Related]
2. Behavioural recovery of rats grafted with dopamine cells after partial striatal dopaminergic depletion in a conditioned reaction-time task.
Moukhles H; Amalric M; Nieoullon A; Daszuta A
Neuroscience; 1994 Nov; 63(1):73-84. PubMed ID: 7898663
[TBL] [Abstract][Full Text] [Related]
3. Dopamine denervation of specific striatal subregions differentially affects preparation and execution of a delayed response task in the rat.
Florio T; Capozzo A; Nisini A; Lupi A; Scarnati E
Behav Brain Res; 1999 Oct; 104(1-2):51-62. PubMed ID: 11125742
[TBL] [Abstract][Full Text] [Related]
4. In a rat model of parkinsonism, lesions of the subthalamic nucleus reverse increases of reaction time but induce a dramatic premature responding deficit.
Baunez C; Nieoullon A; Amalric M
J Neurosci; 1995 Oct; 15(10):6531-41. PubMed ID: 7472415
[TBL] [Abstract][Full Text] [Related]
5. Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease.
Yuan H; Sarre S; Ebinger G; Michotte Y
J Neurosci Methods; 2005 May; 144(1):35-45. PubMed ID: 15848237
[TBL] [Abstract][Full Text] [Related]
6. Dopaminergic neuronal degeneration and motor impairments following axon terminal lesion by instrastriatal 6-hydroxydopamine in the rat.
Lee CS; Sauer H; Bjorklund A
Neuroscience; 1996 Jun; 72(3):641-53. PubMed ID: 9157311
[TBL] [Abstract][Full Text] [Related]
7. Cyclosporin A attenuates the decrease in tyrosine hydroxylase immunoreactivity in nigrostriatal dopaminergic neurons and in striatal dopamine content in rats with intrastriatal injection of 6-hydroxydopamine.
Matsuura K; Makino H; Ogawa N
Exp Neurol; 1997 Aug; 146(2):526-35. PubMed ID: 9270064
[TBL] [Abstract][Full Text] [Related]
8. Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of substantia nigra in rats.
Srinivasan J; Schmidt WJ
Eur J Neurosci; 2003 Jun; 17(12):2586-92. PubMed ID: 12823465
[TBL] [Abstract][Full Text] [Related]
9. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.
Francardo V; Recchia A; Popovic N; Andersson D; Nissbrandt H; Cenci MA
Neurobiol Dis; 2011 Jun; 42(3):327-40. PubMed ID: 21310234
[TBL] [Abstract][Full Text] [Related]
10. Estrogen decreases corpus striatal neurotoxicity in response to 6-hydroxydopamine.
Dluzen D
Brain Res; 1997 Sep; 767(2):340-4. PubMed ID: 9367266
[TBL] [Abstract][Full Text] [Related]
11. Chronic effects of single intrastriatal injections of 6-hydroxydopamine or 1-methyl-4-phenylpyridinium studied by microdialysis in freely moving rats.
Espino A; Cutillas B; Tortosa A; Ferrer I; Bartrons R; Ambrosio S
Brain Res; 1995 Oct; 695(2):151-7. PubMed ID: 8556325
[TBL] [Abstract][Full Text] [Related]
12. Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine.
Przedborski S; Levivier M; Jiang H; Ferreira M; Jackson-Lewis V; Donaldson D; Togasaki DM
Neuroscience; 1995 Aug; 67(3):631-47. PubMed ID: 7675192
[TBL] [Abstract][Full Text] [Related]
13. Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum.
Doucet JP; Nakabeppu Y; Bedard PJ; Hope BT; Nestler EJ; Jasmin BJ; Chen JS; Iadarola MJ; St-Jean M; Wigle N; Blanchet P; Grondin R; Robertson GS
Eur J Neurosci; 1996 Feb; 8(2):365-81. PubMed ID: 8714707
[TBL] [Abstract][Full Text] [Related]
14. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
Hossain MA; Weiner N
J Pharmacol Exp Ther; 1993 Dec; 267(3):1105-11. PubMed ID: 8263772
[TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal dopamine metabolites in rats after intrastriatal administration of 6-hydroxydopamine or 1-methyl-4-phenylpyridinium ion.
Espino A; Llorens J; Calopa M; Bartrons R; Rodriguez-Farré E; Ambrosio S
Brain Res; 1995 Jan; 669(1):19-25. PubMed ID: 7712161
[TBL] [Abstract][Full Text] [Related]
16. Functional investigations into the role of dopamine and serotonin in partial bilateral striatal 6-hydroxydopamine lesioned rats.
Scholtissen B; Deumens R; Leentjens AF; Schmitz C; Blokland A; Steinbusch HW; Prickaerts J
Pharmacol Biochem Behav; 2006 Feb; 83(2):175-85. PubMed ID: 16504275
[TBL] [Abstract][Full Text] [Related]
17. Intracerebroventricular administration of substance P increases dopamine content in the brain of 6-hydroxydopamine-lesioned rats.
Krasnova IN; Bychkov ER; Lioudyno VI; Zubareva OE; Dambinova SA
Neuroscience; 2000; 95(1):113-7. PubMed ID: 10619467
[TBL] [Abstract][Full Text] [Related]
18. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease.
Oiwa Y; Yoshimura R; Nakai K; Itakura T
Brain Res; 2002 Aug; 947(2):271-83. PubMed ID: 12176170
[TBL] [Abstract][Full Text] [Related]
19. Effect of AdGDNF on dopaminergic neurotransmission in the striatum of 6-OHDA-treated rats.
Smith AD; Kozlowski DA; Bohn MC; Zigmond MJ
Exp Neurol; 2005 Jun; 193(2):420-6. PubMed ID: 15869944
[TBL] [Abstract][Full Text] [Related]
20. Induction of D2 dopamine receptor mRNA synthesis in a 6-hydroxydopamine parkinsonian rat model.
Lisovoski F; Haby C; Borrelli E; Schleef C; Revel MO; Hindelang C; Zwiller J
Brain Res Bull; 1992 May; 28(5):697-701. PubMed ID: 1535533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
